menu
    • menu
    [{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Alpibectir","moa":"||Transcription factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ GSK"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"EDCTP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Alpibectir","moa":"||Transcription factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVersys AG \/ EDCTP","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ EDCTP"}]

    Find Clinical Drug Pipeline Developments & Deals for Atina

    Menu

    Atina

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioVersys AG

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            BioVersys AG

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alpibectir,Ethionamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioVersys Expands Collaboration with GSK, Extending Series C Round by CHF 12.3 Million

                            Details : The collaboration with the GSK to accelerate the clinical development of BVL-GSK098 (alpibectir) for the treatment of tuberculosis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            May 07, 2024

                            Lead Product(s) : Alpibectir,Ethionamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioVersys AG

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            BioVersys AG

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alpibectir,Ethionamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : EDCTP

                            Deal Size : $2.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            BioVersys, TASK and GSK Receive 2.7 Million Euro from EDCTP for Phase 2a Clinical Trial

                            Details : The funding aims to advance the development of BVL-GSK098 (alpibectir) in combination withethionamide for treating Drug-Susceptible Pulmonary Tuberculosis in adult.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            February 25, 2021

                            Lead Product(s) : Alpibectir,Ethionamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : EDCTP

                            Deal Size : $2.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth